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Poster Session I 85daily amphotericin (31%). Fungal prophylaxis was started pre-
transplant at 85% of the institutions, day 11 (15%) of the institu-
tions. Fungal prophylaxis was stopped with immunosuppressive
therapy at 69% of the centers, day 121 (7%), day 1100 (7%) and
17% of reporting institutions did not specify. Ninety-three percent
of the institutions used prophylaxis for cGVHD patients.
Fifty-percent routinely screen for fungal infections after day 0 in
both autologous and allogeneic transplants, utilizing weekly culture
surveillance (23%), fever only (25%), fever/clinical evidence (45%)
and by Glactamann assay (7%). Fungal organisms screened for in-
cluded Canididia (53%), Histoplasma (31%), Crytpotococcus
(15%), Aspergillus (85%), Zygomyces (45%) and Fusarium (31%).
The majority reported using hepa-filtered rooms and hand wash-
ing. N-95 masks (31%) were part of BMT isolation policy and 11%
used gowns. There were age specific visitor restrictions at 50% of
the institutions with no visitors under an age range of 12 to15 years
old.
Based on the submitted surveys the PBMTC institutions employ
various fungalmanagement practices. These findings suggest a need
to develop a fungal management standard of care for the pediatric
BMT patient. Further exploration of practices and outcomes is
needed to expand evidence based fungal management practices in
the pediatric BMT patient.228
RESOLUTION OF IPEX AND ACHIEVEMENT OF COMPLETE DONOR
CD31CD41 T-CELL ENGRAFTMENT FOLLOWING A REDUCED INTEN-
SITY CONDITIONING REGIMEN AND INFUSION OF A T- AND B-LYMPHO-
CYTE DEPLETED ALLOGENEIC BONE MARROW GRAFT
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Immune dysregulation, polyendocrinopathy, enteropathy, X-
linked syndrome (IPEX) is a rare autoimmune disease, historically
resulting in death by 2 years of age. IPEX is characterized by muta-
tions in FOXP3, resulting in aberrant function of CD41CD25bright
regulatory T cells (Treg). Treg are critical regulators of immune
responses and dysfunctional activity results in unchecked im-
mune-mediated disease. Allogeneic hematopoietic stem cell trans-
plantation (HSCT) is the only potential cure, yet traditional
myeloablative conditioning, tends to be detrimental to this popula-
tion. Our patient, who has a FOXP3 missense mutation at 1150
G.A, presented with severe enteropathy, failure to thrive, psoriasi-
form dermatitis, and sepsis in early infancy. Prior to HSCT at 8
months of age, he developed autoimmune hemolytic anemia while
receiving immunosuppressive therapy. For HSCT, he received a
reduced intensity conditioning (RIC) regimen consisting of
Campath-1H, fludarabine, thiotepa, and melphalan, followed by
a T- and B-cell depleted matched unrelated donor bone marrow
graft with 5  106 CD31 cells/kg added back to facilitate engraft-
ment. Cyclosporine was continued for graft-versus-host disease
prophylaxis. Due to his severe enteropathy he received palifermin
3 days prior to beginning RIC and 3 days after HSCT. Condition-
ing and stem cell infusion were well tolerated. The patient achieved
myeloid engraftment (ANC . 500/mm3) on day 113 and platelet
engraftment (.50,000/mm3) on day 137. He reveals no clinical
signs of IPEX, including resolution of enteropathy and reduction
in serum IgE from 299 International units (IU)/ml to 4 IU/ml at
day 127; this marker remains within normal limits. Initial periph-
eral blood chimerism by VNTR analysis was 100%, yet decreased
over time, leading to the discontinuation of cyclosporine on day
191. To determine presence of Treg, myeloid and lymphocyte sub-
sets were purified by cell-sorting and analyzed by VNTR when cell
populations were . 10,000 cells. Well-defined CD31CD41 and
CD31CD81 T-cell populations were . 89% donor, with the
Treg population being 98% donor. Myeloid and NK cells and B
lymphocytes exhibit mixed chimerism 5 months after HSCT. Lym-
phocyte responses to mitogens were normal at day 1152. In sum-
mary, we have demonstrated that a child with IPEX can tolerate
HSCT with a RIC regimen and a T- and B-cell depleted graft
with minimal toxicity and achieve full Treg lymphocyte engraft-
ment in the presence of a mixed donor chimerism.229
TWICE-DAILY INTRAVENOUS (IV) BUSULFAN (Bu) X 4 DAYS IN CHIL-
DREN UNDERGOING A REDUCED-INTENSITY CONDITIONING (RIC)
REGIMEN WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION (AlloHSCT) IS SAFE ANDWELL-TOLERATED BUT RESULTS
IN SIGNIFICANTLY INCREASED Bu CLEARANCE (CL) AND DECREASED
AREA UNDER THE CURVE (AUC) AND HALF-LIFE (t1/2) WHEN COM-
PARED TO IV BU TWICE-DAILY DOSING PHARMACOKINETICS (PK) IN
ADULTS
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Inaccurate Bu dosing duringHSCTconditioning can result in in-
creased graft failure or excessive regimen-related toxicity. IV Bu is
safe and effective in pediatric HSCT recipients at a dose of 4 mg/
kg/day (#4 yr) or 3.2 mg/kg/day (.4 yr) using q6 h  16 dosing
but Bu PK is age-dependent (Wall, Blood, 2000a). Q12 h  8 dos-
ing has been shown to be safe and effective in adults, withmean first-
dose AUC 3576 mmol*min, t1/2 3.46 h and CL 1.88 ml/min/kg
(Fernandez, BBMT, 2002). However, Bu safety and PK data is lack-
ing for q12 h  8 dosing in pediatric HSCT recipients. We studied
15 pediatric pts, mean age 9.5 yr (1.4–20.9 yr) with malignant (n 5
5) and nonmalignant (n 5 10) conditions who underwent RIC for
alloHSCT with IV Bu q12 h  8 dosing (4 mg/kg/day [\ 4 yr];
3.2 mg/kg/day [$4 yr]), fludarabine (30 mg/m2/day  5 days) and
alemtuzumab (54 mg/m2/5 days). Phenytoin/fosphenytoin load
was given prior to start of Bu; maintenance continued 48 h post-
Bu. Donor sources were: 3 6/6 & 1 5/6 matched-related donor, 1
10/10, 2 9/10 & 2 8/10 MUD, 2 6/6 related cord blood (CB) and
4 4/6 unrelated CB. PK samples (n 5 12) were obtained at hr 1,
2, 3, 5, 6, 7 and 8 after start of 1st dose. Bu levels were measured
by a GC-MS method on heparinized plasma. Results are summa-
rized in Table I. Target Css was 600–900 ng/ml. 5 pts required
dose increases; 1 was dose-reduced. Mean CL (ml/min/kg) for\4
yr (n 5 3) was significantly higher than in $4 yr (4.59 6 0.52 v
3.45 6 0.72, p 5 .0326). Difference between mean Bu t1/2 for\4
yr v $4 yr trended toward but did not reach significance (1.94 h
6 0.46 v 2.57 h6 0.59, p5 0.13). 2 pts (13%) had seizures unrelated
to Bu; there was no VOD. Donor chimerism was 80% at D1 30 (n
5 13) and 90% at D 1 60 (n 5 11). 1 of 15 pts had primary graft
failure; this pt also had the 2nd highest Bu CL (4.77 ml/min/kg),
lowest t1/2 (1.62 h) and 2nd lowest AUC (1648 mmol*min). In sum-
mary, we demonstrated significantly lower AUC and t1/2 and signif-
icantly increased CL when compared to adult q12h dosing PK data,
suggesting that q12h IV Bu PK may depend on patient age (Table
I).We also found a significant age-dependent (\4 yr v$4 yr) differ-
ence in Bu CL, possibly due to increased glutathione-S-transferase
activity (Gibbs, Drug Metab Dispos, 1999). Furthermore, we
showed that q12h IV Bu in pediatric pts results in low toxicity
and high engraftment post-RIC regimen. Additional pediatric sub-
jects are needed to determine if increased Bu CL and decreased
AUC result in increased risk of graft failure.Busulfan pharmacokinetic data for q12 hour dosing in pediatric and adult
patients
AUC mmol*min t1⁄2 , hr CL, ml/min/kg Vd, L Css ng/ml(mean ± SD) (mean ± SD) (mean ± SD) (mean ± SD) (mean ± SD)Pediatric
(n 5 12;
n 5 11 for
AUC & VD1900 ± 383 2.41 ± 0.61 3.74 ± 0.83 22.8 ± 14.6 653 ± 125Adult (n 5 6)
(Fernandez,
BBMT,
2002)3576 ± 740 3.46 ± 0.38 1.88 ± 0.37 Not
ReportedNot
Reportedp-value p\.0001 p5.0015 p5.0001 NA NA
